Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
CLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, has exercised its option to license Abeona's patented AAV204 capsid for use in potential gene therapies for a range of prevalent and rare retinal diseases that result in blindness. This worldwide, non-exclusive license is pursuant to the agreement between Abeona and Beacon, announced in July 2024, to evaluate the therapeutic potential of AAV204.
AAV204, a novel AAV capsid from the AIM™ capsid library licensed by Abeona from the University of North Carolina at Chapel Hill, has been shown to achieve high macular and optic nerve transduction levels after para-retinal administration and has also been shown to facilitate transduction of both the inner and outer retina after intravitreal administration in mice and non-human primates.
'Beacon's option exercise further validates AAV204's potential to enable targeted delivery of gene therapies in rare and prevalent ophthalmic diseases,' said Dr. Madhav Vasanthavada, Chief Commercial Officer and Head of Business Development at Abeona Therapeutics. 'Our non-exclusive agreement with Beacon enables us to fully explore the therapeutic value of AAV204 in additional ophthalmic diseases.'
The exercise of this license option concludes Beacon's initial evaluation of the AAV204 capsid for development and commercialization of gene therapies and gives Beacon the right to use AAV204 in connection with up to five gene or ophthalmology disease targets. Under the terms of the agreement, Abeona will receive an undisclosed upfront license payment with additional payments upon the achievement of certain development, regulatory, and sales milestones, along with tiered royalties on worldwide net sales for licensed products incorporating AAV204.
About the AIM™ capsid libraryThe AIM™ capsid library is a collection of novel AAV serotypes that target delivery of genetic payloads to key tissues implicated in devastating genetic diseases, including the central nervous system (including the retina), lungs, eye, muscle, liver and other tissues, with potentially improved tropism profiles. AIM™ vectors have shown the potential to evade the immune response generated by exposure to naturally-occurring AAV vectors in preclinical studies. AAV204 is covered by U.S. Patent Nos. 10,532,110 and 10,561,743.
About Abeona TherapeuticsAbeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona's ZEVASKYN™ (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company's fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company's development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona's novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN™, Abeona Assist™, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Forward-Looking Statements This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as 'may,' 'will,' 'believe,' 'anticipate,' 'expect,' 'intend,' 'potential,' and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to commercialize ZEVASKYN, the therapeutic potential of ZEVASKYN, whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company's expectations, continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections from the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company's most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
CONTACT: Investor and Media Contact: Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Cluely's ARR doubled in a week to $7M, founder Roy Lee says. But rivals are coming.
Cluely's revenue has skyrocketed to about $7 million in ARR since it launched its new enterprise product a week ago, founder Roy Lee told TechCrunch. 'Every single person who has a meeting or an interview is testing this out.' Cluely, one of Silicon Valley's most-talked-about startups, offers products that use AI to analyze online conversations, deliver real-time notes, provide context, and suggest questions to ask. This information appeared discreetly on the user's screen, invisible to others. For weeks leading up to the product reveal, Lee boasted that the company's annual recurring revenue (ARR) exceeded $3 million and that the startup was profitable. The increase in interest is coming from consumers and businesses alike, he said. Cluely is a startup born of controversy after Lee posted in a viral X thread saying he was suspended by Columbia University because he and a co-founder developed a tool to cheat on job interviews for software engineers. He turned around and created a product and startup out of the tech, originally using the marketing tagline that it helps you 'cheat on everything.' Now that it is backed by big-league VCs like Andreessen Horowitz, Abstract Ventures, and Susa Ventures, it has toned down its marketing to 'Everything You Need. Before You Ask. … This feels like cheating.' It has turned into a Silicon Valley sensation from its rage-bait marketing. But the startup's controversial history hasn't stopped businesses from showing interest in Cluely's product, Lee insists, telling us that it has signed a public company that just this week doubled its annual contract with Cluely to $2.5 million. Lee declined to name the company. The enterprise version of the product is similar to the consumer offering, but it comes with some extra features such as team management and additional security settings, Lee said. Business use cases include sales calls, customer support, and remote tutoring. Which Cluely features are the most interesting to customers? According to Lee, it's Cluely's ability to take real-time notes. 'Meeting notes have been a proven very sticky, very interesting AI use case. The only problem with them is they're all post-call,' Lee said of competitors' products. 'You want to look back at them in the middle of a meeting, and that is what we offer.' However, Cluely's real-time notetaker may be easy to replicate. On Thursday, Pickle, a company that describes itself as a digital clone factory, claimed on X that it built Glass, an open source, free product with very similar functionality to Cluely. By mid-day it had already garnered over 850 stars and been forked nearly 150 times — indicating that the open source developer community is giving this free version a try. Time will tell if Cluely's meteoric rise can withstand competition from free copycat products like Glass. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
Slate Auto drops ‘under $20,000' pricing after Trump administration ends federal EV tax credit
Slate Auto, the electric vehicle startup backed by Jeff Bezos, has stopped promoting that its upcoming pickup truck will start 'under $20,000' following passage of President Trump's tax cut bill. The bill, which is expected to be signed into law by Trump on July 4, will cause the federal EV tax credit to end in September — a $7,500 incentive that Slate had counted on to help its all-electric pickup clear that mark. When Slate came out of stealth mode in April, the startup heavily promoted that its all-electric pickup would start at 'under $20,000' with the $7,500 federal EV tax credit. That language was still on Slate's website as recently as yesterday according to the Web Archive. The change is a potential blow to the young company's attempt to make a radically affordable electric vehicle. Slate didn't provide a precise price for the EV at its launch event; and it has yet to say what the actual starting price of its vehicle will be, sans-credit. A Slate spokesperson declined to comment on the change. The company won't start building the truck until the end of 2026 at the earliest. Slate's business is also built around making this vehicle highly customizable, which means it's possible that few people will buy the base model to begin with. The sub-$20,000 price had been a big attraction point for the brand new company's product, and it was a major focus following its April launch event. The auto industry has 'driven prices to a place that most Americans simply can't afford,' chief commercial officer Jeremy Snyder said during the event. 'But we're here to change that.' 'We are building the affordable vehicle that has long been promised but never been delivered,' CEO Chris Barman added at the time. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Trump's ‘Big Beautiful Bill' Cements GOP Dominance
Speaker of the House Mike Johnson (R-LA) and President Donald Trump, speak to members of the media as they depart a House Republican meeting at the U.S. Capitol on May 20, 2025 in Washington, DC. Credit - Andrew Harnik—Getty Images The passage of the 'Big Beautiful Bill' on Thursday was a moment when President Donald Trump's hold on the Republican Party was tested — and he won. GOP holdouts objected to the trillions of dollars the bill is projected to add to the debt and the cuts to Medicaid and other safety net programs. But in the end, Trump was able to browbeat Republicans into supporting his costly plans to fund long-term tax cuts for the wealthy, more deportations of immigrants and boosting defense spending. Trump's victory further strengthens his power in Washington and clears the way for him to take even more aggressive actions on immigration, trade policy and depart from American tradition to hammer the chair of the Federal Reserve Jerome Powell into lowering interest rates, a move that could give the U.S. economy a sugar high of cheap cash. Read more: The Budget Bill's Big Consequences Trump's control over the GOP 'is as close to total as any President has ever had over his own political party,' says Whit Ayres, a long-time Republican pollster. 'It gives him the support of his own legislative caucus for almost anything he wants to do.' Trump plans to sign the bill into law on Friday at 5 p.m. as B-2 bombers jet over the White House during a Fourth of July celebration for military families. 'We'll be signing with those beautiful planes flying right over our heads,' Trump told reporters traveling with him on Air Force One on Thursday evening. In order to get the bill passed, some Republicans broke their promises not to cut Medicaid, other Republicans reneged on pledges to keep down the national debt. In the House, only two Republicans—Rep. Thomas Massie of Kentucky and Rep. Brian Fitzpatrick of Pennsylvania—ended up voting against Trump's bill. The bill narrowly passed the House 218-214 with all Democrats voting against it. Massie wrote on X that he voted 'no' because 'it will significantly increase U.S. budget deficits in the near term, negatively impacting all Americans through sustained inflation and high interest rates.' The bill barely made it out of the Senate earlier in the week. Republican Senators Susan Collins of Maine, Rand Paul of Kentucky and Thom Tillis of North Carolina voted against Trump's bill forcing Vice President J.D. Vance to cast a tie-breaking vote. Tillis said the Medicaid cuts would be devastating to his state, and, after bucking Trump, said he wouldn't run for reelection. Republican Senator Josh Hawley of Missouri had argued against the cuts to Medicaid but ended up voting 'yes,' and Senator Ron Johnson of Wisconsin, a Republican, had criticized the bill for not cutting enough to offset adding trillions to the debt, but ended up voting for the bill. Read more: The GOP Budget Will Balloon the National Debt. Here's What Trump Could do to Fix it Now Trump is faced with the daunting task of selling the unpopular bill to the public. Only 29% of voters said they support the bill, according to a Quinnipiac University poll published on June 26, while 55% percent of voters said that they oppose the bill and 16% were unsure. The cuts to social safety net programs and the increase in the deficit could lead to political blowback that helps Democrats take back control of the House in the 2026 mid-term elections. The bill could be a political risk for Trump, says Ayres, if 'a whole lot of Trump supporters lose their health care and get angry about it.' Contact us at letters@
